nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—melanoma	0.526	1	CbGaD
Linagliptin—CYP3A4—Temozolomide—melanoma	0.144	0.376	CbGbCtD
Linagliptin—ABCB1—Dactinomycin—melanoma	0.0874	0.229	CbGbCtD
Linagliptin—CYP3A4—Vemurafenib—melanoma	0.0788	0.206	CbGbCtD
Linagliptin—ABCB1—Docetaxel—melanoma	0.0451	0.118	CbGbCtD
Linagliptin—CYP3A4—Docetaxel—melanoma	0.027	0.0708	CbGbCtD
Linagliptin—Pain in extremity—Vemurafenib—melanoma	0.00256	0.031	CcSEcCtD
Linagliptin—Skin exfoliation—Bleomycin—melanoma	0.00204	0.0247	CcSEcCtD
Linagliptin—Infestation NOS—Vemurafenib—melanoma	0.00197	0.0239	CcSEcCtD
Linagliptin—Infestation—Vemurafenib—melanoma	0.00197	0.0239	CcSEcCtD
Linagliptin—Skin exfoliation—Carmustine—melanoma	0.00178	0.0216	CcSEcCtD
Linagliptin—Skin exfoliation—Temozolomide—melanoma	0.00172	0.0208	CcSEcCtD
Linagliptin—Mediastinal disorder—Vemurafenib—melanoma	0.0016	0.0193	CcSEcCtD
Linagliptin—Diabetes mellitus—Carmustine—melanoma	0.00156	0.0188	CcSEcCtD
Linagliptin—Malnutrition—Vemurafenib—melanoma	0.00154	0.0187	CcSEcCtD
Linagliptin—Back pain—Vemurafenib—melanoma	0.00149	0.0181	CcSEcCtD
Linagliptin—Cough—Vemurafenib—melanoma	0.00134	0.0163	CcSEcCtD
Linagliptin—Myalgia—Vemurafenib—melanoma	0.00131	0.0159	CcSEcCtD
Linagliptin—Arthralgia—Vemurafenib—melanoma	0.00131	0.0159	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.0013	0.0158	CcSEcCtD
Linagliptin—Anaphylactic shock—Vemurafenib—melanoma	0.00126	0.0152	CcSEcCtD
Linagliptin—Infection—Vemurafenib—melanoma	0.00125	0.0151	CcSEcCtD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)—PAX6—melanoma	0.00123	0.129	CbGpPWpGaD
Linagliptin—Skin disorder—Vemurafenib—melanoma	0.00122	0.0148	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00115	0.0139	CcSEcCtD
Linagliptin—Skin exfoliation—Docetaxel—melanoma	0.00114	0.0139	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Vemurafenib—melanoma	0.00109	0.0132	CcSEcCtD
Linagliptin—Constipation—Vemurafenib—melanoma	0.00108	0.013	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Temozolomide—melanoma	0.00105	0.0127	CcSEcCtD
Linagliptin—Weight increased—Temozolomide—melanoma	0.00103	0.0125	CcSEcCtD
Linagliptin—Urinary tract infection—Carmustine—melanoma	0.00101	0.0123	CcSEcCtD
Linagliptin—Infestation—Temozolomide—melanoma	0.00101	0.0122	CcSEcCtD
Linagliptin—Infestation NOS—Temozolomide—melanoma	0.00101	0.0122	CcSEcCtD
Linagliptin—Urinary tract infection—Temozolomide—melanoma	0.00098	0.0119	CcSEcCtD
Linagliptin—Hypersensitivity—Vemurafenib—melanoma	0.000927	0.0112	CcSEcCtD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—PAX6—melanoma	0.00091	0.0949	CbGpPWpGaD
Linagliptin—Pain in extremity—Docetaxel—melanoma	0.00087	0.0105	CcSEcCtD
Linagliptin—Diarrhoea—Vemurafenib—melanoma	0.00086	0.0104	CcSEcCtD
Linagliptin—Immune system disorder—Temozolomide—melanoma	0.000817	0.0099	CcSEcCtD
Linagliptin—Mediastinal disorder—Temozolomide—melanoma	0.000815	0.00988	CcSEcCtD
Linagliptin—Malnutrition—Carmustine—melanoma	0.000815	0.00987	CcSEcCtD
Linagliptin—Cough—Bleomycin—melanoma	0.000815	0.00987	CcSEcCtD
Linagliptin—DPP4—Incretin synthesis, secretion, and inactivation—PAX6—melanoma	0.00081	0.0844	CbGpPWpGaD
Linagliptin—Myalgia—Bleomycin—melanoma	0.000795	0.00963	CcSEcCtD
Linagliptin—Rash—Vemurafenib—melanoma	0.000793	0.00961	CcSEcCtD
Linagliptin—Dermatitis—Vemurafenib—melanoma	0.000792	0.0096	CcSEcCtD
Linagliptin—Back pain—Carmustine—melanoma	0.000788	0.00955	CcSEcCtD
Linagliptin—Headache—Vemurafenib—melanoma	0.000788	0.00954	CcSEcCtD
Linagliptin—Malnutrition—Temozolomide—melanoma	0.000788	0.00954	CcSEcCtD
Linagliptin—Nasopharyngitis—Docetaxel—melanoma	0.000778	0.00942	CcSEcCtD
Linagliptin—Anaphylactic shock—Bleomycin—melanoma	0.000762	0.00923	CcSEcCtD
Linagliptin—Back pain—Temozolomide—melanoma	0.000762	0.00923	CcSEcCtD
Linagliptin—Infection—Bleomycin—melanoma	0.000757	0.00917	CcSEcCtD
Linagliptin—Myalgia—Dactinomycin—melanoma	0.000741	0.00898	CcSEcCtD
Linagliptin—Angioedema—Temozolomide—melanoma	0.00072	0.00872	CcSEcCtD
Linagliptin—Infection—Dactinomycin—melanoma	0.000706	0.00855	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Bleomycin—melanoma	0.000694	0.00841	CcSEcCtD
Linagliptin—Myalgia—Carmustine—melanoma	0.000694	0.0084	CcSEcCtD
Linagliptin—Cough—Temozolomide—melanoma	0.000687	0.00833	CcSEcCtD
Linagliptin—Weight increased—Docetaxel—melanoma	0.000684	0.00829	CcSEcCtD
Linagliptin—Arthralgia—Temozolomide—melanoma	0.00067	0.00812	CcSEcCtD
Linagliptin—Myalgia—Temozolomide—melanoma	0.00067	0.00812	CcSEcCtD
Linagliptin—Infestation—Docetaxel—melanoma	0.00067	0.00812	CcSEcCtD
Linagliptin—Infestation NOS—Docetaxel—melanoma	0.00067	0.00812	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000666	0.00807	CcSEcCtD
Linagliptin—Infection—Carmustine—melanoma	0.000661	0.008	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000647	0.00784	CcSEcCtD
Linagliptin—Anaphylactic shock—Temozolomide—melanoma	0.000643	0.00779	CcSEcCtD
Linagliptin—Infection—Temozolomide—melanoma	0.000639	0.00774	CcSEcCtD
Linagliptin—Skin disorder—Temozolomide—melanoma	0.000624	0.00756	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Carmustine—melanoma	0.000606	0.00734	CcSEcCtD
Linagliptin—Urticaria—Bleomycin—melanoma	0.000605	0.00733	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Temozolomide—melanoma	0.000586	0.00709	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Carmustine—melanoma	0.000574	0.00696	CcSEcCtD
Linagliptin—Constipation—Carmustine—melanoma	0.000569	0.00689	CcSEcCtD
Linagliptin—Hypersensitivity—Bleomycin—melanoma	0.000561	0.0068	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Temozolomide—melanoma	0.000555	0.00672	CcSEcCtD
Linagliptin—Constipation—Temozolomide—melanoma	0.00055	0.00666	CcSEcCtD
Linagliptin—Immune system disorder—Docetaxel—melanoma	0.000543	0.00658	CcSEcCtD
Linagliptin—Mediastinal disorder—Docetaxel—melanoma	0.000542	0.00657	CcSEcCtD
Linagliptin—Malnutrition—Docetaxel—melanoma	0.000524	0.00634	CcSEcCtD
Linagliptin—Hypersensitivity—Dactinomycin—melanoma	0.000524	0.00634	CcSEcCtD
Linagliptin—Urticaria—Temozolomide—melanoma	0.000511	0.00619	CcSEcCtD
Linagliptin—Back pain—Docetaxel—melanoma	0.000507	0.00614	CcSEcCtD
Linagliptin—Hypersensitivity—Carmustine—melanoma	0.00049	0.00594	CcSEcCtD
Linagliptin—Diarrhoea—Dactinomycin—melanoma	0.000486	0.00589	CcSEcCtD
Linagliptin—Rash—Bleomycin—melanoma	0.00048	0.00582	CcSEcCtD
Linagliptin—Dermatitis—Bleomycin—melanoma	0.00048	0.00581	CcSEcCtD
Linagliptin—Hypersensitivity—Temozolomide—melanoma	0.000474	0.00574	CcSEcCtD
Linagliptin—Cough—Docetaxel—melanoma	0.000457	0.00554	CcSEcCtD
Linagliptin—Diarrhoea—Carmustine—melanoma	0.000455	0.00551	CcSEcCtD
Linagliptin—Rash—Dactinomycin—melanoma	0.000448	0.00543	CcSEcCtD
Linagliptin—Arthralgia—Docetaxel—melanoma	0.000446	0.0054	CcSEcCtD
Linagliptin—Myalgia—Docetaxel—melanoma	0.000446	0.0054	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000443	0.00536	CcSEcCtD
Linagliptin—Diarrhoea—Temozolomide—melanoma	0.00044	0.00533	CcSEcCtD
Linagliptin—Anaphylactic shock—Docetaxel—melanoma	0.000427	0.00518	CcSEcCtD
Linagliptin—Infection—Docetaxel—melanoma	0.000425	0.00514	CcSEcCtD
Linagliptin—Rash—Carmustine—melanoma	0.000419	0.00508	CcSEcCtD
Linagliptin—Dermatitis—Carmustine—melanoma	0.000419	0.00508	CcSEcCtD
Linagliptin—Headache—Carmustine—melanoma	0.000417	0.00505	CcSEcCtD
Linagliptin—Skin disorder—Docetaxel—melanoma	0.000415	0.00503	CcSEcCtD
Linagliptin—Rash—Temozolomide—melanoma	0.000405	0.00491	CcSEcCtD
Linagliptin—Dermatitis—Temozolomide—melanoma	0.000405	0.0049	CcSEcCtD
Linagliptin—Headache—Temozolomide—melanoma	0.000403	0.00488	CcSEcCtD
Linagliptin—ABCB1—ABC-family proteins mediated transport—ABCB5—melanoma	0.000392	0.0408	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Docetaxel—melanoma	0.000389	0.00472	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Docetaxel—melanoma	0.000369	0.00447	CcSEcCtD
Linagliptin—Constipation—Docetaxel—melanoma	0.000366	0.00443	CcSEcCtD
Linagliptin—Hypersensitivity—Docetaxel—melanoma	0.000315	0.00381	CcSEcCtD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CTNNB1—melanoma	0.000307	0.032	CbGpPWpGaD
Linagliptin—Diarrhoea—Docetaxel—melanoma	0.000292	0.00354	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—PAX6—melanoma	0.000275	0.0286	CbGpPWpGaD
Linagliptin—DPP4—Incretin synthesis, secretion, and inactivation—CTNNB1—melanoma	0.000273	0.0285	CbGpPWpGaD
Linagliptin—Rash—Docetaxel—melanoma	0.00027	0.00326	CcSEcCtD
Linagliptin—Dermatitis—Docetaxel—melanoma	0.000269	0.00326	CcSEcCtD
Linagliptin—Headache—Docetaxel—melanoma	0.000268	0.00324	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—ADAMTS20—melanoma	0.000169	0.0176	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—PIGU—melanoma	0.000169	0.0176	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—ARL2—melanoma	0.000155	0.0161	CbGpPWpGaD
Linagliptin—CYP3A4—Liver X Receptor Pathway—FASN—melanoma	0.000143	0.015	CbGpPWpGaD
Linagliptin—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—melanoma	0.000142	0.0148	CbGpPWpGaD
Linagliptin—CYP3A4—Codeine and Morphine Metabolism—ABCB1—melanoma	0.000129	0.0134	CbGpPWpGaD
Linagliptin—DPP4—Peptide hormone metabolism—IGF1—melanoma	0.000125	0.013	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—ARNT—melanoma	0.000122	0.0127	CbGpPWpGaD
Linagliptin—ABCB1—Drug Induction of Bile Acid Pathway—VDR—melanoma	0.000114	0.0119	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—SLC17A5—melanoma	0.000113	0.0118	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—ADAMTS13—melanoma	0.000109	0.0114	CbGpPWpGaD
Linagliptin—DPP4—Peptide hormone metabolism—CTNNB1—melanoma	9.27e-05	0.00966	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—NDRG1—melanoma	8.92e-05	0.0093	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—MCL1—melanoma	8.92e-05	0.0093	CbGpPWpGaD
Linagliptin—CYP3A4—Estrogen metabolism—CYP1B1—melanoma	8.17e-05	0.00851	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—RPS3—melanoma	8.13e-05	0.00847	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—melanoma	7.3e-05	0.0076	CbGpPWpGaD
Linagliptin—CYP3A4—Tamoxifen metabolism—CYP1B1—melanoma	7.22e-05	0.00752	CbGpPWpGaD
Linagliptin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—melanoma	7.04e-05	0.00733	CbGpPWpGaD
Linagliptin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—melanoma	7.02e-05	0.00732	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—melanoma	6.73e-05	0.00702	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—GAB2—melanoma	6.67e-05	0.00695	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—melanoma	6.64e-05	0.00692	CbGpPWpGaD
Linagliptin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—melanoma	6.55e-05	0.00682	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—FOXP3—melanoma	6.06e-05	0.00632	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—ETS1—melanoma	6.03e-05	0.00628	CbGpPWpGaD
Linagliptin—CYP3A4—Irinotecan Pathway—APC—melanoma	5.93e-05	0.00618	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—EPO—melanoma	5.31e-05	0.00553	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—PAX6—melanoma	5.18e-05	0.0054	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—HSPA5—melanoma	4.98e-05	0.00519	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—CXCR4—melanoma	4.94e-05	0.00515	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—UGT2B10—melanoma	4.78e-05	0.00499	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CAPN1—melanoma	4.73e-05	0.00493	CbGpPWpGaD
Linagliptin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	4.57e-05	0.00476	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—melanoma	4.55e-05	0.00475	CbGpPWpGaD
Linagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—melanoma	4.24e-05	0.00442	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CTLA4—melanoma	4.17e-05	0.00435	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ABCB5—melanoma	4.09e-05	0.00426	CbGpPWpGaD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—melanoma	4.04e-05	0.00421	CbGpPWpGaD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—melanoma	4.03e-05	0.0042	CbGpPWpGaD
Linagliptin—CYP3A4—Tryptophan metabolism—CYP1B1—melanoma	3.85e-05	0.00402	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—NODAL—melanoma	3.81e-05	0.00397	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—EDN1—melanoma	3.79e-05	0.00395	CbGpPWpGaD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—melanoma	3.7e-05	0.00386	CbGpPWpGaD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—melanoma	3.65e-05	0.00381	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—melanoma	3.53e-05	0.00368	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP10—melanoma	3.4e-05	0.00354	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAP3K5—melanoma	3.4e-05	0.00354	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CD86—melanoma	3.31e-05	0.00345	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—TERT—melanoma	3.3e-05	0.00344	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL10—melanoma	3.25e-05	0.00338	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—HIF1A—melanoma	3.16e-05	0.00329	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL4—melanoma	3.16e-05	0.00329	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—melanoma	3.14e-05	0.00327	CbGpPWpGaD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	3.12e-05	0.00325	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—PDGFRA—melanoma	3.11e-05	0.00324	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—HLA-B—melanoma	3.09e-05	0.00322	CbGpPWpGaD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—melanoma	3.08e-05	0.00321	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—APAF1—melanoma	3.05e-05	0.00318	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—AKR1B10—melanoma	3.04e-05	0.00317	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—FASLG—melanoma	3.02e-05	0.00314	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	3e-05	0.00313	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—MMP1—melanoma	2.95e-05	0.00307	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—FAS—melanoma	2.91e-05	0.00303	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—melanoma	2.89e-05	0.00301	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—NOS2—melanoma	2.87e-05	0.00299	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—HLA-A—melanoma	2.86e-05	0.00298	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ARL2—melanoma	2.84e-05	0.00295	CbGpPWpGaD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	2.81e-05	0.00293	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—HLA-DRB1—melanoma	2.61e-05	0.00272	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—melanoma	2.54e-05	0.00265	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	2.53e-05	0.00263	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CD80—melanoma	2.41e-05	0.00252	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—IGF1—melanoma	2.36e-05	0.00246	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—MMP2—melanoma	2.28e-05	0.00238	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CASP8—melanoma	2.24e-05	0.00234	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC15A2—melanoma	2.15e-05	0.00224	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC17A5—melanoma	2.07e-05	0.00216	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—melanoma	1.94e-05	0.00202	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IFNG—melanoma	1.91e-05	0.00199	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—CXCL8—melanoma	1.9e-05	0.00198	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC6A11—melanoma	1.88e-05	0.00196	CbGpPWpGaD
Linagliptin—CYP3A4—Tryptophan metabolism—MDM2—melanoma	1.8e-05	0.00188	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CXCL8—melanoma	1.77e-05	0.00185	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—CTNNB1—melanoma	1.75e-05	0.00182	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CASP3—melanoma	1.7e-05	0.00177	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL2—melanoma	1.7e-05	0.00177	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—melanoma	1.69e-05	0.00176	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—melanoma	1.66e-05	0.00173	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP17A1—melanoma	1.59e-05	0.00166	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FGF1—melanoma	1.58e-05	0.00165	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP17A1—melanoma	1.57e-05	0.00164	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—E2F1—melanoma	1.55e-05	0.00161	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—melanoma	1.53e-05	0.0016	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PRKCA—melanoma	1.52e-05	0.00158	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—melanoma	1.49e-05	0.00155	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—melanoma	1.46e-05	0.00152	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ACER3—melanoma	1.45e-05	0.00151	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—VEGFA—melanoma	1.44e-05	0.0015	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—melanoma	1.44e-05	0.0015	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—melanoma	1.41e-05	0.00147	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP1B1—melanoma	1.34e-05	0.0014	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—melanoma	1.34e-05	0.00139	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—UGT2B10—melanoma	1.33e-05	0.00138	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP1B1—melanoma	1.32e-05	0.00138	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—melanoma	1.27e-05	0.00132	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—melanoma	1.26e-05	0.00132	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—TNF—melanoma	1.24e-05	0.00129	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HS3ST5—melanoma	1.23e-05	0.00129	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—melanoma	1.19e-05	0.00124	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—melanoma	1.18e-05	0.00122	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—melanoma	1.11e-05	0.00115	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—melanoma	1.09e-05	0.00113	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—AKT1—melanoma	1.06e-05	0.00111	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—melanoma	1.05e-05	0.0011	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—melanoma	1e-05	0.00104	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—melanoma	9.5e-06	0.00099	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—melanoma	9.37e-06	0.000976	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PLCB4—melanoma	9.36e-06	0.000975	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—melanoma	9.23e-06	0.000962	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—melanoma	9.03e-06	0.000941	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ACER3—melanoma	8.95e-06	0.000932	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC6A11—melanoma	8.8e-06	0.000917	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIP4K2A—melanoma	8.8e-06	0.000917	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC5A5—melanoma	8.59e-06	0.000895	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MTAP—melanoma	8.56e-06	0.000892	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	8.55e-06	0.000891	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	8.38e-06	0.000873	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—UGT2B10—melanoma	8.18e-06	0.000853	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	8.16e-06	0.00085	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	8.08e-06	0.000842	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	7.89e-06	0.000822	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	7.87e-06	0.00082	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	7.84e-06	0.000817	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—LUM—melanoma	7.63e-06	0.000795	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PHGDH—melanoma	7.63e-06	0.000795	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HS3ST5—melanoma	7.61e-06	0.000793	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HPSE—melanoma	7.48e-06	0.00078	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CUBN—melanoma	7.34e-06	0.000765	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	7.11e-06	0.000741	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SDHD—melanoma	7.09e-06	0.000739	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CSPG4—melanoma	7.09e-06	0.000739	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—BSG—melanoma	7.09e-06	0.000739	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GPAM—melanoma	6.87e-06	0.000716	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	6.73e-06	0.000701	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—melanoma	6.54e-06	0.000682	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	6.4e-06	0.000667	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	6.4e-06	0.000667	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—melanoma	6.09e-06	0.000635	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	6.05e-06	0.00063	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PLA2G6—melanoma	5.84e-06	0.000609	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PLCB4—melanoma	5.77e-06	0.000601	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	5.55e-06	0.000579	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIP4K2A—melanoma	5.42e-06	0.000565	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC6A11—melanoma	5.42e-06	0.000565	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	5.37e-06	0.00056	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MTAP—melanoma	5.27e-06	0.000549	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—VCAN—melanoma	5.25e-06	0.000547	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—LUM—melanoma	4.7e-06	0.00049	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PHGDH—melanoma	4.7e-06	0.00049	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HPSE—melanoma	4.61e-06	0.00048	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	4.54e-06	0.000473	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CUBN—melanoma	4.52e-06	0.000471	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP17A1—melanoma	4.43e-06	0.000461	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SDHD—melanoma	4.37e-06	0.000455	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—BSG—melanoma	4.37e-06	0.000455	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CSPG4—melanoma	4.37e-06	0.000455	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GPAM—melanoma	4.23e-06	0.000441	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GNA11—melanoma	4.18e-06	0.000436	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	4.1e-06	0.000427	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—FASN—melanoma	4.09e-06	0.000426	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC5A5—melanoma	4.02e-06	0.000419	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GNAQ—melanoma	3.89e-06	0.000405	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CD44—melanoma	3.89e-06	0.000405	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP1B1—melanoma	3.73e-06	0.000388	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PLA2G6—melanoma	3.6e-06	0.000375	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—VCAN—melanoma	3.23e-06	0.000337	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PRKCA—melanoma	2.82e-06	0.000294	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ERCC2—melanoma	2.8e-06	0.000292	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP17A1—melanoma	2.73e-06	0.000284	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GNA11—melanoma	2.58e-06	0.000268	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—FASN—melanoma	2.52e-06	0.000263	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC5A5—melanoma	2.48e-06	0.000258	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GNAQ—melanoma	2.39e-06	0.000249	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CD44—melanoma	2.39e-06	0.000249	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP1B1—melanoma	2.3e-06	0.000239	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CG—melanoma	2.21e-06	0.00023	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PPARG—melanoma	2.13e-06	0.000222	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CD—melanoma	1.94e-06	0.000203	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ALB—melanoma	1.92e-06	0.0002	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCB1—melanoma	1.89e-06	0.000197	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PRKCA—melanoma	1.74e-06	0.000181	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ERCC2—melanoma	1.73e-06	0.00018	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CB—melanoma	1.69e-06	0.000177	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTGS2—melanoma	1.68e-06	0.000175	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTEN—melanoma	1.46e-06	0.000153	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CG—melanoma	1.36e-06	0.000142	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PPARG—melanoma	1.31e-06	0.000137	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CD—melanoma	1.2e-06	0.000125	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ALB—melanoma	1.18e-06	0.000123	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CB—melanoma	1.04e-06	0.000109	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTGS2—melanoma	1.03e-06	0.000108	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CA—melanoma	1.03e-06	0.000108	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTEN—melanoma	9.02e-07	9.4e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AKT1—melanoma	8.44e-07	8.79e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CA—melanoma	6.36e-07	6.63e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AKT1—melanoma	5.2e-07	5.42e-05	CbGpPWpGaD
